ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.96
0.71%
US Tech 100
20,762.73
1.73%
S&P 500
5,942.47
1.26%
US Dollar vs CAD
1.44457
0.00%
Bitcoin
98,259.91
0.05%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Nagarro Se (0AA3) Share Price

Nagarro Se

Nagarro Se (0AA3)

LSE
0.00
0.00
(0.00%)
Closed January 05 10:30AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
-
Bid
0.00
Ask
0.00
Volume
2,335
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
-
Previous Close
0.00
Open
-
Last Trade
1
@
78.35
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
13,776,000
Dividend Yield
-
PE Ratio
21.06
Earnings Per Share (EPS)
3.79
Revenue
922.9M
Net Profit
52.14M

About Nagarro Se

Sector
Management Consulting Svcs
Industry
Management Consulting Svcs
Website
www.nagarro.com
Headquarters
Munich, Deu
Founded
-
Nagarro Se is listed in the Management Consulting Svcs sector of the London Stock Exchange with ticker 0AA3. The last closing price for Nagarro was 0.00 €. Over the last year, Nagarro shares have traded in a share price range of 0.00 € to 0.00 €.

Nagarro currently has 13,776,000 shares outstanding. Nagarro has a price to earnings ratio (PE ratio) of 21.06.

Ask ADVFN Intelligence (AI)

0AA3 Latest News

More News

Nagarro posts 6.1% YoY revenue growth in constant currency in 9M 2024

Nagarro posts 6.1% YoY revenue growth in constant currency in 9M 2024 PR Newswire MUNICH, Nov. 14, 2024 MUNICH, Nov. 14, 2024 /PRNewswire/ -- Today, Nagarro, a global digital engineering leader...

November 14 2024
PR Newswire (US)

Nagarro posts 6.1% YoY revenue growth in constant currency in 9M 2024

Nagarro posts 6.1% YoY revenue growth in constant currency in 9M 2024 PR Newswire MUNICH, Nov. 14, 2024 MUNICH, Nov. 14, 2024 /PRNewswire/ -- Today, Nagarro, a global digital engineering leader...

November 14 2024
PR Newswire (US)

Nagarro fortifies its UK footprint with the strategic acquisition of FWD View Limited

Nagarro fortifies its UK footprint with the strategic acquisition of FWD View Limited PR Newswire MUNICH, Oct. 30, 2024 MUNICH, Oct. 30, 2024 /PRNewswire/ -- Nagarro, a global leader in digital...

October 30 2024
PR Newswire (US)

Nagarro fortifies its UK footprint with the strategic acquisition of FWD View Limited

Nagarro fortifies its UK footprint with the strategic acquisition of FWD View Limited PR Newswire MUNICH, Oct. 30, 2024 MUNICH, Oct. 30, 2024 /PRNewswire/ -- Nagarro, a global leader in digital...

October 30 2024
PR Newswire (US)

Nagarro posts 6.3% YoY revenue growth in constant currency in H1 2024 despite global macroeconomic challenges

Nagarro posts 6.3% YoY revenue growth in constant currency in H1 2024 despite global macroeconomic challenges PR Newswire MUNICH, Aug. 14, 2024 MUNICH, Aug. 14, 2024 /PRNewswire/...

August 14 2024
PR Newswire (US)

Nagarro posts 6.3% YoY revenue growth in constant currency in H1 2024 despite global macroeconomic challenges

Nagarro posts 6.3% YoY revenue growth in constant currency in H1 2024 despite global macroeconomic challenges PR Newswire MUNICH, Aug. 14, 2024 MUNICH, Aug. 14, 2024 /PRNewswire/...

August 14 2024
PR Newswire (US)

Nagarro announces Q1 '24 results, posts profitable growth

Nagarro announces Q1 '24 results, posts profitable growth PR Newswire MUNICH, May 14, 2024 MUNICH, May 14, 2024 /PRNewswire/ -- Today, Nagarro, a global digital engineering leader, presented...

May 14 2024
PR Newswire (US)

Nagarro announces Q1 '24 results, posts profitable growth

Nagarro announces Q1 '24 results, posts profitable growth PR Newswire MUNICH, May 14, 2024 MUNICH, May 14, 2024 /PRNewswire/ -- Today, Nagarro, a global digital engineering leader, presented...

May 14 2024
PR Newswire (US)

Nagarro releases audited results for 2023 -- annual revenue grew 9.4% in constant currency

Nagarro releases audited results for 2023 -- annual revenue grew 9.4% in constant currency PR Newswire MUNICH, April 16, 2024 MUNICH, April 16, 2024 /PRNewswire/ -- Today, Nagarro, a global...

April 16 2024
PR Newswire (US)

Nagarro releases audited results for 2023 -- annual revenue grew 9.4% in constant currency

Nagarro releases audited results for 2023 -- annual revenue grew 9.4% in constant currency PR Newswire MUNICH, April 16, 2024 MUNICH, April 16, 2024 /PRNewswire/ -- Today, Nagarro, a global...

April 16 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

0AA3 - Frequently Asked Questions (FAQ)

What is the current Nagarro share price?
The current share price of Nagarro is 0.00 €
How many Nagarro shares are in issue?
Nagarro has 13,776,000 shares in issue
What is the 1 year trading range for Nagarro share price?
Nagarro has traded in the range of 0.00 € to 0.00 € during the past year
What is the PE ratio of Nagarro?
The price to earnings ratio of Nagarro is 21.06
What is the cash to sales ratio of Nagarro?
The cash to sales ratio of Nagarro is 1.19
What is the reporting currency for Nagarro?
Nagarro reports financial results in EUR
What is the latest annual turnover for Nagarro?
The latest annual turnover of Nagarro is EUR 922.9M
What is the latest annual profit for Nagarro?
The latest annual profit of Nagarro is EUR 52.14M
What is the registered address of Nagarro?
The registered address for Nagarro is EINSTEINSTRA��E 172, MUNICH, 81677
What is the Nagarro website address?
The website address for Nagarro is www.nagarro.com
Which industry sector does Nagarro operate in?
Nagarro operates in the MANAGEMENT CONSULTING SVCS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M

Discussion

View Full Feed
DonVance DonVance 2 minutes ago
This will hit 1k this year I believe now.
MSTR
georgejjl georgejjl 2 minutes ago
How many of the 7 million Alzheimer’s patients in the USA are projected to be treated with the MAB infusions during 2025???

How many people with Alzheimer’s in the USA are projected to be treated with donepezil (Aricept) or memantine during 2025???

The treatment used t
AVXL
Mr. Bill Mr. Bill 3 minutes ago
Stretches https://www.healthline.com/health/back-pain/sciatic-stretches#sitting-spinal-stretch
Graniteguy Graniteguy 4 minutes ago
Doc and Investor posters here tend to be negatively biased which you whole heartedly champion, especially "Doc" who's medical opinion is at best questionable, and incredibly biased, to fit a narrative of constant failure for Anavex's Blarcamesine. The fact that you pile onto their "steaming pile of
AVXL
BDEZ BDEZ 6 minutes ago
The Russes hit the jackpot?
BDEZ BDEZ 7 minutes ago
40% of homicides in the US take place in districts with a Soros-funded prosecutor.

Biden gave him a Medal Of Freedom.

https://x.com/EndWokeness/status/1875725808071012529
BDEZ BDEZ 8 minutes ago
Not good, thanks for sharing.
sand sand 15 minutes ago
Thank you Ducci for all your sharing and insights extremely helpful. I'm slowly diligently getting there rewiring the brain and focusing on what shows the moves. Much continued success this week. Thank you again.
SPY
mining101 mining101 15 minutes ago
Moving hard soon 
EFSH
mining101 mining101 16 minutes ago
Superb
MEGL
benz280c benz280c 23 minutes ago
Speak louder and maybe you will convince somebody that this is how you really feel. No need to be insecure around your fellow investors.
GDVM
rx7171 rx7171 30 minutes ago
In addition MABs are approved for only a limited portion of the AD population, whereas Blarcamasine appears to be effective in 70-80% of the ITT population with its strongest efficacy in the 70% with wild type Sigma-1.
AVXL
TheHound TheHound 31 minutes ago
Learn how to use the bull market support band with that chart and you’ll have a powerful tool under your belt!
XRPUSD
Investor2014 Investor2014 34 minutes ago
When I say that the totality of information is what Anavex rely on it does take into account the pretty ineffective SOC, associated risks and inconveniences for patients.

Still any drug regulatory process must and should look carefully at the data to ensure that neither type one or tw
AVXL
nowwhat2 nowwhat2 39 minutes ago
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
BTCUSD
rx7171 rx7171 40 minutes ago
Yes that spike to $23 in June of 2021 was driven entirely by the excellent Phase II data for PDD.

Yet now after completing the AD 2b/3 trial and having an EMA MAA accepted for evaluation the share price is barely half that number!

I understand the company being very ca
PDD
sunspotter sunspotter 45 minutes ago
Black Cat Moan was one of my favorites back in the day:

https://youtu.be/cxN-frB1UbI?si=Ph6XMC3omR0rRlmR

Edit: auto correct changed Moan to Moana. The cultural prevalence of Disney.
Investor2014 Investor2014 47 minutes ago
The ex-biotech executive is back in the Rett trap posting mode - hope it goes better with the biased approach this time.

Listing all the site PI’s is not world class peer review WGT confirmation.
AVXL
nowwhat2 nowwhat2 48 minutes ago
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
sunspotter sunspotter 50 minutes ago
I rather think you missed the point. It’s not that higher doses of GALT’s drug are toxic, it’s that they are ineffective.

Given the purported mechanism, that almost certainly means lower doses are too, and that the implication that the lower dose worked is merely an artefact.
GALT
nowwhat2 nowwhat2 53 minutes ago
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
XRPUSD
CrossFireTrader CrossFireTrader 56 minutes ago
I try to avoid Krispy Kreme's af all costs. Thanks for your insight...
GDVM
skitahoe skitahoe 56 minutes ago
Dstock, you may be very right about the data from compassionate use being included, but if it is, I would think that the protocols used on every one of those patients would need to be included as none are specifically on the trial protocol. It's essentially anecdotal evidence, but it could all add
NWBO

Your Recent History

LSE
0AA3
Nagarro
NASDAQ
ASST
Asset Entities
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads